Drugs / PLR001
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05007652 Background | Sep 2021 → Oct 2022 | lymphoid neoplasm | Kyowa Kirin, Inc. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLR001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05007652 ↗ |
| Known as | plerixafor | “KRN125(pegfilgrastim), PLR001(plerixafor)” NCT05007652 ↗ |
| Route | Subcutaneous | “The concomitant drug PLR001 is administered subcutaneously once daily at a dose of 0.24 mg/kg” NCT05007652 ↗ |